| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A A Vaag, J J Holst, A Vølund, H B Beck-Nielse. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. European journal of endocrinology. vol 135. issue 4. 1996-12-30. PMID:8921824. |
incremental glp-1 responses correlated with incremental insulin responses in the combined study population (n = 37; r = 0.42, p = 0.01). |
1996-12-30 |
2023-08-12 |
Not clear |
| A A Vaag, J J Holst, A Vølund, H B Beck-Nielse. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. European journal of endocrinology. vol 135. issue 4. 1996-12-30. PMID:8921824. |
in conclusion, a decreased intestinal glp-1 secretion may contribute to the abnormal insulin secretion during oral glucose ingestion in niddm twins. |
1996-12-30 |
2023-08-12 |
Not clear |
| A A Vaag, J J Holst, A Vølund, H B Beck-Nielse. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. European journal of endocrinology. vol 135. issue 4. 1996-12-30. PMID:8921824. |
however, decreased secretion of gut incretin hormones (glp-1 or gip) does not explain all of the defects of pancreatic insulin secretion in niddm patients/twins or in non-diabetic individuals (identical twins) with a genetic predisposition to niddm. |
1996-12-30 |
2023-08-12 |
Not clear |
| P A Martin, A Faulkne. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep. The Journal of endocrinology. vol 151. issue 1. 1996-12-23. PMID:8943774. |
the effects of intravenous somatostatin-28 (s28) infusion on glucose-stimulated and glucagon-like peptide-1(7-36)amide (glp-1)-augmented insulin secretion were studied in sheep. |
1996-12-23 |
2023-08-12 |
Not clear |
| P A Martin, A Faulkne. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep. The Journal of endocrinology. vol 151. issue 1. 1996-12-23. PMID:8943774. |
glp-1 significantly augmented glucose-stimulated insulin secretion, serum concentrations increasing from about 230 to 280 pmol/l. |
1996-12-23 |
2023-08-12 |
Not clear |
| C Orskov, A Wettergren, J J Hols. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scandinavian journal of gastroenterology. vol 31. issue 7. 1996-12-06. PMID:8819215. |
the insulinotropic hormones gastric inhibitory polypeptide (gip) and glucagon-like peptide-1 (glp-1), secreted from the k-cells of the upper small intestine and from the l-cells of the lower small intestine, respectively, are thought to be responsible for intestinal stimulation of insulin secretion. |
1996-12-06 |
2023-08-12 |
Not clear |
| P M Jehle, D Jehle, R D Fussgänger, G Adle. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 103 Suppl 2. 1996-12-04. PMID:8839251. |
glucagon-like peptide-1 (glp-1) is the major incretin hormone from the distal small intestine which stimulates basal and glucose-induced insulin secretion. |
1996-12-04 |
2023-08-12 |
rat |
| P M Jehle, D Jehle, R D Fussgänger, G Adle. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 103 Suppl 2. 1996-12-04. PMID:8839251. |
1980) we investigated the effects of glp-1 on insulin secretion, insulin content, and insulin receptor binding. |
1996-12-04 |
2023-08-12 |
rat |
| P M Jehle, D Jehle, R D Fussgänger, G Adle. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 103 Suppl 2. 1996-12-04. PMID:8839251. |
during a 1 hour incubation, glp-1 [1 nm] stimulated insulin secretion 2-fold (p < 0.01 vs controls). |
1996-12-04 |
2023-08-12 |
rat |
| P M Jehle, D Jehle, R D Fussgänger, G Adle. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 103 Suppl 2. 1996-12-04. PMID:8839251. |
incubating rinm5f for 24 h with glp-1 [1 nm], a 1.6-fold higher cellular insulin content was observed (p < 0.01 vs controls). |
1996-12-04 |
2023-08-12 |
rat |
| P M Jehle, D Jehle, R D Fussgänger, G Adle. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 103 Suppl 2. 1996-12-04. PMID:8839251. |
taken together, in rinm5f insulinoma cells glp-1 potently stimulates insulin secretion and insulin content, and improves insulin receptor binding. |
1996-12-04 |
2023-08-12 |
rat |
| M Toft-Nielsen, A Hvidberg, J Hilsted, H Dige-Petersen, J J Hols. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects. Diabetic medicine : a journal of the British Diabetic Association. vol 13. issue 6. 1996-12-03. PMID:8799658. |
plasma glp-1 levels were similar on the two glp-1 infusion days and resulted in: (1) a significant decrease in plasma glucose from 5.2 +/- 0.2 to 4.1 +/- 0.1 mmol l-1 with glp-1/propranolol infusion, and from 5.2 +/- 0.1 to 4.0 +/- 0.1 mmol l-1 with glp-1/saline infusion (ns); (2) a corresponding significant increase in plasma insulin from 58.0 +/- 6.3 to 144.5 +/- 22.3 pmol l-1 and from 61.7 +/- 6.4 to 148.2 +/- 34.0 pmol l-1, respectively (ns); (3) a significant decrease in plasma glucagon from 11.7 +/- 1.6 to 6.5 +/- 1.5 pmol l-1 and from 10.4 +/- 1.6 to 4.6 +/- 1.0 pmol l-1, respectively; (4) a significant decrease in the rate of glucose appearance which was not significantly different on the two glp-1 infusion days; and (5) an increase in catecholamine levels in the glp-1/saline experiment and also in the beta-blockade experiments. |
1996-12-03 |
2023-08-12 |
human |
| C Widmann, W Dolci, B Thoren. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Molecular endocrinology (Baltimore, Md.). vol 10. issue 1. 1996-12-02. PMID:8838146. |
glucagon-like peptide-1 (glp-1) stimulates glucose-induced insulin secretion by binding to a specific g protein-coupled receptor linked to activation of the adenylyl cyclase pathway. |
1996-12-02 |
2023-08-12 |
Not clear |
| C Widmann, W Dolci, B Thoren. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Molecular endocrinology (Baltimore, Md.). vol 10. issue 1. 1996-12-02. PMID:8838146. |
together, our results indicate that the production of camp and, hence, the stimulation of insulin secretion induced by glp-1 can be negatively modulated by homologous and heterologous desensitization, mechanisms that involve receptor phosphorylation. |
1996-12-02 |
2023-08-12 |
Not clear |
| J Rachman, F M Gribble, B A Barrow, J C Levy, K D Buchanan, R C Turne. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes. vol 45. issue 11. 1996-11-29. PMID:8866556. |
glucagon-like peptide 1 (glp-1) is a natural enteric incretin hormone, which is a potent insulin secretogogue in vitro and in vivo in humans. |
1996-11-29 |
2023-08-12 |
human |
| J Rachman, F M Gribble, B A Barrow, J C Levy, K D Buchanan, R C Turne. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes. vol 45. issue 11. 1996-11-29. PMID:8866556. |
we compared the effects of overnight intravenous infusion of glp-1 (7-36) amide with saline infusion, on overnight plasma concentrations of glucose, insulin, and glucagon in eight subjects with niddm. |
1996-11-29 |
2023-08-12 |
human |
| J Rachman, F M Gribble, B A Barrow, J C Levy, K D Buchanan, R C Turne. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes. vol 45. issue 11. 1996-11-29. PMID:8866556. |
the glp-1 infusion was continued, and the first- and second-phase insulin responses to a 2-h 13 mmol/l hyperglycemic clamp and the insulin response to a subsequent bolus of the nonglucose secretogogue, arginine, were measured. |
1996-11-29 |
2023-08-12 |
human |
| J Rachman, F M Gribble, B A Barrow, J C Levy, K D Buchanan, R C Turne. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes. vol 45. issue 11. 1996-11-29. PMID:8866556. |
the effects on stimulated beta-cell function of lowering plasma glucose per se were assessed by a separate overnight infusion of soluble insulin, the rate of which was adjusted to mimic the blood glucose profile achieved with glp-1. |
1996-11-29 |
2023-08-12 |
human |
| J Rachman, F M Gribble, B A Barrow, J C Levy, K D Buchanan, R C Turne. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes. vol 45. issue 11. 1996-11-29. PMID:8866556. |
first-phase incremental insulin response to glucose was improved by glp-1 from 8 pmol/l (-8-33) to 116 pmol/l (12-438) (p < 0.005), second-phase insulin response to glucose from 136 pmol/l (53-352) to 1,156 pmol/l (357-3,748) (p < 0.0002), and incremental insulin response to arginine from 443 pmol/l (172-1,144) to 811 pmol/l (272-2,417) (p < 0.002). |
1996-11-29 |
2023-08-12 |
human |
| E M Plisetskaya, T P Mommse. Glucagon and glucagon-like peptides in fishes. International review of cytology. vol 168. 1996-11-15. PMID:8843650. |
ultimately, glp-1 and glucagon exert effects on glucose metabolism that directly and indirectly oppose several key actions of insulin. |
1996-11-15 |
2023-08-12 |
Not clear |